Pulmonx (LUNG) investor relations material

Market opportunity and clinical need

• Emphysema is a severe form of COPD, among the top four causes of death globally, with poor quality of life for patients.

• Existing treatments ranged from medical management to invasive lung volume reduction surgery.

• There was a clear need for a less invasive solution for patients with significant air trapping.

Technology and patient selection

• Developed a minimally invasive valve system targeting hyperinflated lung lobes to reduce air trapping.

• Patient identification involves CT scans, StratX reports, and the Chartis procedure to confirm candidacy.

• Valves are placed in a short hospital stay, improving lung function, quality of life, and exercise capacity.

Clinical evidence and reimbursement

• Four randomized controlled trials published in leading journals showed clinically meaningful and statistically significant benefits.

• The technology is now part of standard care and included in GOLD guidelines for COPD.

• Achieved high reimbursement rates: 100% for Medicare and 95% for commercial payers.